ProteoGenix

ProteoGenix is a contract research organization (CRO) specializing in antibody discovery, engineering, and early-stage development. The company provides a comprehensive suite of services, including custom antibody generation, recombinant protein expression, gene synthesis, and peptide synthesis. They employ diverse technologies—such as phage display, hybridoma generation, and single B cell screening—to support biotech, pharmaceutical, and academic partners from target identification through to preclinical candidate selection. Their proprietary tools, such as the XtenCHO™ expression system, are designed to enhance protein yields and optimize development timelines. Based in France with a presence in the United States, ProteoGenix focuses on solving complex biological challenges by integrating scientific expertise with advanced engineering and in silico insights.

This work is critical for researchers and companies operating under strict scientific and time constraints, as it allows them to de-risk the development of therapeutic antibodies and diagnostic tools. By assigning dedicated PhD-level experts to individual projects, ProteoGenix provides tailored strategies that address unique technical goals while maintaining rigorous quality standards, reflected in their ISO 9001 and 14001 certifications. Their ability to manage the entire lifecycle of antibody production—from initial design and engineering to characterization and stable cell line development—enables partners to accelerate their path toward clinical applications and market readiness. The company has over two decades of experience collaborating with global clients to turn complex scientific ambitions into viable, research-ready achievements.